Article
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.
Cancer discovery - 1 May 2024
Rubinson Douglas A, Tanaka Noritaka, Fece de la Cruz Ferran, Kapner Kevin S, Rosenthal Michael H, Norden Bryanna L, Barnes Haley, Ehnstrom Sara, Morales-Giron Alvin A, Brais Lauren K, Lemke Christopher T, Aguirre Andrew J, Corcoran Ryan B
Abstract excerpt
KRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors. Because amino acid sequences of the three main RAS isoforms-KRAS, NRAS, and HRAS-are highly similar, we hypothesized that some KRASG12C inhibitors might also target NRASG12C and/or HRASG12C, which are less common but...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.